Promising leukemia combo trial for kids ends early

NCT ID NCT03860844

Terminated Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 19 times

Summary

This study tested a drug called isatuximab added to standard chemotherapy for children aged 28 days to under 18 years whose leukemia (ALL or AML) had returned or stopped responding to treatment. The goal was to see if the combination could help achieve complete remission. The trial was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Children's Medical Center of Dallas-Site Number:8400002

Dallas, Texas, 75235, United States
Investigational Site Number :0320002

CABA, Buenos Aires, C1181ACH, Argentina
Investigational Site Number :0320004

Buenos Aires, C1245AAM, Argentina
Investigational Site Number :0320005

Buenos Aires, C1118AAT, Argentina
Investigational Site Number :0320006

Capital Federal, Buenos Aires, C1425DUC, Argentina
Investigational Site Number :0760001

São Paulo, São Paulo, 08270-070, Brazil
Investigational Site Number :0760004

São Paulo, São Paulo, 4023-062, Brazil
Investigational Site Number :0760006

Curitiba, Paraná, 81520-060, Brazil
Investigational Site Number :0760007

Porto Alegre, Rio Grande do Sul, 90035 003, Brazil
Investigational Site Number :0760009

Ribeirão Preto, São Paulo, 14048-900, Brazil
Investigational Site Number :0760010

Jaú, São Paulo, 17210-070, Brazil
Investigational Site Number :0760013

Curitiba, Paraná, 80250-060, Brazil
Investigational Site Number :2080001

Copenhagen, 2100, Denmark
Investigational Site Number :2500001

Paris, 75571, France
Investigational Site Number :2500002

Lille, 59037, France
Investigational Site Number :2500003

Lyon, 69008, France
Investigational Site Number :2500004

Paris, 75935, France
Investigational Site Number :2760003

Hamburg, 20246, Germany
Investigational Site Number :2760005

Erlangen, 91054, Germany
Investigational Site Number :2760006

Münster, 48149, Germany
Investigational Site Number :3000001

Athens, 115 27, Greece
Investigational Site Number :3480002

Budapest, 1094, Hungary
Investigational Site Number :3800001

Monza, Lombardy, 20900, Italy
Investigational Site Number :3800002

Genoa, Liguria, 16147, Italy
Investigational Site Number :3800003

Turin, Piedmont, 10126, Italy
Investigational Site Number :3800005

Verona, Veneto, 37126, Italy
Investigational Site Number :4100001

Seoul, Seoul-teukbyeolsi, 03080, South Korea
Investigational Site Number :4100002

Seoul, Seoul-teukbyeolsi, 06351, South Korea
Investigational Site Number :4100004

Seoul, Seoul-teukbyeolsi, 137-701, South Korea
Investigational Site Number :4840001

Monterrey, Nuevo León, 64460, Mexico
Investigational Site Number :4840005

Col. Rancho Menchaca, Querétaro, 76140, Mexico
Investigational Site Number :5280001

Utrecht, 3584 CS, Netherlands
Investigational Site Number :5780001

Bergen, 5021, Norway
Investigational Site Number :5780002

Oslo, 0342, Norway
Investigational Site Number :6040001

Arequipa, Peru
Investigational Site Number :6040002

Lima, 34, Peru
Investigational Site Number :6200001

Lisbon, 1099-023, Portugal
Investigational Site Number :6200002

Coimbra, 3000-602, Portugal
Investigational Site Number :6200003

Porto, 4200-162, Portugal
Investigational Site Number :7520001

Gothenburg, 416 85, Sweden
Sarah Cannon Research Institute-Site Number:8400001

Nashville, Tennessee, 37203, United States

Conditions

Explore the condition pages connected to this study.

ACUTE LYMPHOBLASTIC LEUKEMIA ACUTE MYELOID LEUKEMIA